Pathophysiology and clinic of IgA Nephropathy: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i7.46378Keywords:
IgA nephropathy; Renal disease; Biomarkers; Biopsy; Clinical manifestations.Abstract
Introduction: Immunoglobulin A nephropathy (IgAN) predominantly affects children and young adults, with clinical presentation influenced by factors such as ethnicity and age. Currently, there are no reliable serum or urinary biomarkers for diagnosing IgAN, nor is there a specific treatment for the condition. Therefore, this study aims to explore aspects of renal disease to address current knowledge gaps. Methodology: This is an integrative review on IgAN. Data were gathered from the Virtual Health Library (BVS), Scientific Electronic Library Online (SciELO), and the National Library of Medicine (PubMed), using the intersection of the keywords "IgA nephropathy," "renal disease," "biomarkers," "biopsy," and "clinical manifestations" to address the question formulated through the PICO strategy. Results and Discussion: The epidemiology of IgAN is poorly understood, but it is known to be more prevalent in males, children, and young adults. The pathogenesis involves the production of anomalous IgA following triggers such as infections or vigorous exercise, which are targeted by autoantibodies forming immune complexes deposited in the renal glomeruli. This leads to histological changes that manifest in various clinical presentations, primarily visible hematuria. Definitive diagnosis requires biopsy, and prognosis depends primarily on the degree of proteinuria and remaining renal function. Current treatment involves supportive measures for blood pressure and proteinuria control, with immunosuppression considered for severe cases. Conclusion: There are still controversies regarding the pathology and treatment of IgAN. Thus, further studies are needed to clarify optimal clinical management and risk factors for the condition.
References
Bharati, J., & Jhaveri, K. D. (2023). Prognosis of IgA Nephropathy: A Lifetime Story. Clinical journal of the American Society of Nephrology: CJASN, 18(6), 699–701. https://doi.org/10.2215/CJN.0000000000000171
Cheung, C. K., & Barratt, J. (2019). Biomarkers to Predict Progression in IgA Nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 14(10), 1421–1423. https://doi.org/10.2215/CJN.09100819
Floege, J., Rauen, T., & Tang, S. C. W. (2021). Current treatment of IgA nephropathy. Seminars in immunopathology, 43(5), 717–728. https://doi.org/10.1007/s00281-021-00888-3
Gutiérrez, E., Carvaca-Fontán, F., Luzardo, L., Morales, E., Alonso, M., & Praga, M. (2020). A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges. Nephron, 144(11), 555–571. https://doi.org/10.1159/000509997
Haaskjold, Y. L., & Knoop, T. (2022). IgA-nefropati. Tidsskrift for Den Norske Legeforening. https://doi.org/10.4045/tidsskr.22.0146
Kiryluk, K., Freedberg, D. E., Radhakrishnan, J., Segall, L., Jacobson, J. S., Mathur, M., Mohan, S., & Neugut, A. I. (2023). Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360, 4(8), 1112–1122. https://doi.org/10.34067/KID.0000000000000165
Li, X., Zeng, M., Liu, J., Zhang, S., Liu, Y., Zhao, Y., Wei, C., Yang, K., Huang, Y., Zhang, L., & Xiao, L. (2023). Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis. BMC medical genomics, 16(1), 63. https://doi.org/10.1186/s12920-023-01494-y
Maixnerova, D., & Tesar, V. (2020). Emerging Modes of Treatment of IgA Nephropathy. International journal of molecular sciences, 21(23), 9064. https://doi.org/10.3390/ijms21239064
Medjeral-Thomas, N. R., Cook, H. T., & Pickering, M. C. (2021). Complement activation in IgA nephropathy. Seminars in immunopathology, 43(5), 679–690. https://doi.org/10.1007/s00281-021-00882-9
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., Gale, D. P., & Barratt, J. (2023). Long-Term Outcomes in IgA Nephropathy. Clinical journal of the American Society of Nephrology: CJASN, 18(6), 727–738. https://doi.org/10.2215/CJN.0000000000000135
Rajasekaran, A., Julian, B. A., & Rizk, D. V. (2021). IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American journal of the medical sciences, 361(2), 176–194. https://doi.org/10.1016/j.amjms.2020.10.003
Reich, H. N., & Floege, J. (2022). How I Treat IgA Nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 17(8), 1243–1246. https://doi.org/10.2215/CJN.02710322
Sallustio, F., Curci, C., Di Leo, V., Gallone, A., Pesce, F., & Gesualdo, L. (2019). A New Vision of IgA Nephropathy: The Missing Link. International journal of molecular sciences, 21(1), 189. https://doi.org/10.3390/ijms21010189
Schimpf, J., Kronbichler, A., Windpessl, M., Zitt, E., Eller, K., Säemann, M. D., Lhotta, K., & Rudnicki, M. (2023). Diagnostik und Therapie IgA Nephropathie – 2023 [Diagnosis and Treatment of IgA Nephropathy-2023]. Wiener klinische Wochenschrift, 135(Suppl 5), 621–627. https://doi.org/10.1007/s00508-023-02257-6
Selvaskandan, H., Shi, S., Twaij, S., Cheung, C. K., & Barratt, J. (2020). Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. Frontiers in immunology, 11, 572754. https://doi.org/10.3389/fimmu.2020.572754
Souza, M. T., Silva, M. D., Carvalho, R. (2010). Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8(1), 102-106. https://doi.org/10.1590/s1679-45082010rw1134
Tashakkorinia, N., Muco, E., & Tudor, M. E. (2021). Berger Disease. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499998/
Tortajada, A., Gutierrez, E., Pickering, M. C., Terente, M. P., & Medjeral-Thomas, N. (2019) The role of complement in IgA nephropathy. Molecular Immunology, 114, 123-132. https://doi.org/10.1016/j.molimm.2019.07.017
Wang, S., Qin, A., Dong, L., Tan, J., Zhou, X., & Qin, W. (2023). Association of obesity with the development of end stage renal disease in IgA nephropathy patients. Frontiers in endocrinology, 14, 1094534. https://doi.org/10.3389/fendo.2023.1094534
Zhong, X., & Ding, J. (2023). Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children. Pediatric nephrology (Berlin, Germany), 38(6), 1707–1715. https://doi.org/10.1007/s00467-022-05798-6
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Milena Figueiredo Campos; Luiza Melgaço Martins; Pedro Luccas Leal Contini Sanches; Eduarda Naves Gonçalves de Almeida; Caio Antônio Lucena de Oliveira; Noeme Rocha Pereira Campos; Aline Lopes Zacarias e Silva; Luiz Eduardo Alencar de Souza; Arthur Augusto Sa Anacleto; Gabriel Starling Costa; Maria Thereza de Oliveira Araújo; Rafella Uzeloto de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
